Option Care Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPCH research report →
Range $22 – $32.05
Price Chart
About the company
Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses.
- CEO
- John C. Rademacher
- IPO
- 1996
- Employees
- 6,528
- HQ
- Bannockburn, IL, US
Get TickerSpark's AI analysis on OPCH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.73B
- P/E
- 22.76
- Fwd P/E
- 16.80
- PEG
- 2.41
- P/S
- 0.82
- P/B
- 3.58
- EV/EBITDA
- 13.46
- Div Yield
- 0.00%
- Gross Margin
- 18.48%
- Op Margin
- 5.96%
- Net Margin
- 3.74%
- ROE
- 16.36%
- ROIC
- 9.41%
Latest fiscal year · YoY change
- Revenue
- $5.65B+13.0%
- Gross Profit
- $1.02B+0.7%
- Op Income
- $337.91M
- Net Income
- $207.59M-2.0%
- EPS
- $1.28+4.1%
- OCF Growth
- -20.1%
- FCF Growth
- -24.5%
- 52W High
- $36.80
- 52W Low
- $18.01
- 50D MA
- $28.71
- 200D MA
- $26.07
- Beta
- 0.58
- RSI (14)
- 70
- Avg Volume
- 4.14M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Option Care Health beat expectations in Q2 with stronger revenue, EBITDA, EPS and cash flow, while reiterating full-year guidance and pointing to improving commercial execution and CID stabilization.· July 29, 2026
- Q2 revenue was $1.4 billion, up 2% year over year and up 7% sequentially.
- Adjusted EBITDA was $117.5 million, up 3% year over year and up 12% sequentially; adjusted EPS was $0.45, up $0.04 from last year.
- Operating cash flow was very strong at $184 million, and net debt leverage ended at 2.1x.
- The company repurchased $150 million of stock in the quarter, representing nearly 5% of shares outstanding.
- Management said acute kept growing in the high single digits, CID patient census stabilized and rose sequentially, and IG neuro and rare/orphan were both solid growth areas.
Revenue in the second quarter was $1.4 billion, up 2% versus last year and up 7% sequentially. Gross profit dollars grew 2% sequentially but were slightly down versus last year; SG&A was down 3% year over year to approximately 11% of revenue. Adjusted EBITDA was $117.5 million, up 3% year over year and up 12% sequentially, and adjusted EPS was $0.45, up $0.04 year over year. Operating cash flow was $184 million and net debt leverage was 2.1x. Full-year 2026 guidance remains revenue of $5.675 billion to $5.775 billion, adjusted EBITDA of $480 million to $495 million, and adjusted EPS of $1.85 to $1.92; operating cash flow target remains at least $320 million. For Q3, management expects sequential revenue growth in the low to mid-single digits and sequential EBITDA growth in the mid-single digit range.
John Charles Rademacher framed the quarter as proof that the turnaround and strategic initiatives are starting to work, but he repeatedly said he is still not satisfied with performance. He highlighted the company’s national scale with local responsiveness, citing strength in acute, improvement in chronic, and expansion in clinics, technology, and AI-enabled workflow tools. His tone was constructive and confident, with emphasis on building momentum through the back half of 2026 and into 2027 rather than declaring victory.
Meenal Sethna emphasized that the quarter came in ahead of expectations and that the company generated strong cash, with $184 million of operating cash flow and 2.1x net debt leverage. She said the company repurchased $150 million of stock in Q2 and that current guidance does not assume any new buybacks beyond that action. She also reiterated the CID-related headwinds: roughly 600 basis points of revenue headwinds and $55 million of gross profit headwinds for 2026, while noting Stelara and related biosimilars are expected to be less than 1% of 2026 net revenue and gross profit. She narrowed full-year adjusted EBITDA and EPS ranges, kept revenue guidance unchanged, and said SG&A growth should remain at or slightly below gross profit growth.
Analysts focused on the implied Q3/Q4 ramp, the mix between acute and chronic, and whether the back-half improvement depended on cost cuts. Management said the guidance is mainly driven by revenue growth from commercial investments, CID census recovery, and ongoing technology/process improvements, with cost actions as a supporting factor rather than the main driver. Questions also covered competitive infusion dynamics, white-bagging, CVS/Stelara formulary changes, and possible CMS home infusion coverage expansion; management said the CMS proposal is narrow and likely not material, and that they have not seen a significant white-bagging impact. On capital allocation, management clarified that no incremental buybacks are embedded in guidance.
Management sees multiple organic growth levers improving at once: acute is still growing in high single digits, CID census stabilized in Q2, IG neuro remains strong, and rare/orphan is also expanding. The company is also seeing benefits from commercial restructuring, technology deployment, clinic expansion, and better operating efficiency, all while maintaining a strong balance sheet and returning capital through buybacks.
CID remains a headwind in 2026, with management still modeling about 600 basis points of revenue pressure and $55 million of gross profit pressure. Management also acknowledged that some new rare/orphan therapies will not go live until late 2026 or early 2027, and that timing depends partly on approvals and launch execution. Analysts pressed on whether the back-half ramp relies too much on sequential improvement, and management said 2027 is still too early to quantify.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.2%
- Shares Outstanding
- 149.80M
- Float Shares
- 147.17M
of shares held by institutions
391 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for OPCH, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 22.29M | ▲ 180.35K |
| Vanguard Group Inc | 16.65M | ▼ 1.04M |
| Wellington Management Group Llp | 9.86M | ▼ 1.92M |
| Vanguard Portfolio Management LLC | 7.97M | ▼ 305.77K |
| Vanguard Capital Management LLC | 6.74M | ▼ 326.38K |
| Fuller & Thaler Asset Management, Inc. | 6.59M | ▼ 861.92K |
| Dimensional Fund Advisors LP | 6.31M | ▲ 860.49K |
| State Street Corp | 6.14M | ▼ 1.69K |
| Arrowstreet Capital, Limited Partnership | 6.12M | ▲ 143.18K |
| Durable Capital Partners LP | 5.29M | ▼ 870.32K |
| Geode Capital Management, LLC | 4.38M | ▼ 85.07K |
| Fmr LLC | 3.72M | ▲ 1.90M |
Held by 451 ETFs
Biggest fund positions in OPCH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Pate R Carter | sell | 6,092 |
| Nov 11, 26 | Pate R Carter | sell | 400 |
| Jul 6, 26 | Bhatia Prateek | other | 23,409 |
| Jul 6, 26 | Bhatia Prateek | other | 16,386 |
| Jul 6, 26 | Bhatia Prateek | other | 0 |
| May 20, 26 | Bierbower Elizabeth D | other | 8,997 |
| May 20, 26 | Deckmann Natasha | other | 844 |
| May 20, 26 | Deckmann Natasha | other | 8,997 |
| May 20, 26 | KRAEMER HARRY M JANSEN JR | other | 12,079 |
| May 20, 26 | KRAEMER HARRY M JANSEN JR | other | 8,997 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OPCH coverage
Recent articles, reports, and earnings notes.
No research on OPCH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPCH report →Are FULC, DSGR, OPCH Obtaining Fair Deals for their Shareholders?
prnewswire.com · Nov 18
Option Care Health Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Option Care Health, Inc. - OPCH
businesswire.com · Nov 17
Option Care (OPCH) Q3 Earnings and Revenues Surpass Estimates
zacks.com · Nov 4
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?
globenewswire.com · Nov 4
Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2026
globenewswire.com · Nov 4
InfuSystem (NYSE:INFU) versus Option Care Health (NASDAQ:OPCH) Head to Head Review
defenseworld.net · Nov 4
Are OPCH, PTC, RXO Obtaining Fair Deals for their Shareholders?
prnewswire.com · Nov 3
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?
prnewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.